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To the Editor:
We have read the recent review on the ambiguous results of block-ing the cytokine pathway published in Critical Care Explorations by Rizvi and Gallo De Moraes (1) with great interest. The authors 
made a compelling argument that blocking the single cascade of cytokine re-
sponse was not successful in diverse conditions such as bacterial sepsis and 
acute respiratory distress syndrome (ARDS). We agree that the currently avail-
able evidence does not support the use of anticytokine therapy or cytokine re-
moval in these settings (2). However, there is mounting evidence from both 
observational studies, including some published in Critical Care Explorations, 
and multicentre randomized clinical trials that interleukin (IL)-6 receptor in-
hibition could indeed significantly reduce mortality in a single agent caused 
viral sepsis, such as coronavirus disease 2019 (COVID-19) (3–6). There is sig-
nificant biological plausibility for manipulating the IL-6 pathway as multiple 
observational studies have shown that IL-6 levels are associated with mor-
tality and morbidity, and it was recently demonstrated that genetic variants 
in the IL-6 pathway are associated with life-threatening disease in critically ill 
COVID-19 patients (7–9). Since the publication of their review, several other 
well-conducted clinical trials have reported their results using tocilizumab or 
sarilumab in COVID-19 (6–11). By summarizing these published studies, and 
the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trials results 
from a preprint, a fixed-effects meta-analysis yields an odds ratio for mortality 
of 0.86 (95% CI, 0.77–0.96) for IL-6-receptor inhibition versus standard care 
(Fig. 1) (12). The included trials were generally at low risk of bias, and we did 
not detect significant heterogeneity. Among the trials with data available in 
the public domain, only the two largest, publicly funded studies have shown 
benefit.
In addition to reduction in mortality, the Randomised, Embedded, Multi-
factorial, Adaptive Platform Trial for Community-Acquired Pneumonia 
(REMAP-CAP) trial has found significant reduction in organ support needs 
and reduction in length of ICU stay in the IL-6 receptor blockade arms, while 
the RECOVERY trial reported significantly less progression to mechanical ven-
tilation or death in those patients who only needed supplemental oxygen on 
randomization (6, 12). This is especially important as these data could inform 
further modeling of healthcare resource needs during the pandemic, where 
stretched ICU capacity has been linked to adverse outcomes (13, 14).
What could be the mechanism for this significant mortality reduction, when 
our own data also suggest that true hyperinflammation and “cytokine storm” 
is a rare phenomenon in severe COVID-19 (15)? IL-6 has several diverse func-
tions and effects, apart from being a potent proinflammatory cytokine. It has 
been shown to inhibit Human Leukocyte Antigen – DR isotype (HLA-DR) ex-
pression on monocytes and decrease interferon-gamma production by CD4 
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cells, contributing to the immune paralysis seen in 
sepsis (16). IL-6 receptor inhibitors may rescue the 
HLA-DR expression on monocytes, increase the abso-
lute lymphocyte count and in turn increase the host’s 
ability to produce interferon-gamma, which has signif-
icant antiviral effects (17). It is possible that the IL-6-
receptor blockade is indeed not inhibiting the runaway 
inflammatory response in COVID-19 but that it helps 
to reinvigorate the normal antiviral response in a host 
shackled with immune paralysis.
Importantly, the trials that produced significant 
results recruited patients whose clinical condition 
was at least on the moderate to severe state on the 
World Health Organization scale and, in these stud-
ies, the majority of patients have received concurrent 
corticosteroids (6, 12). The patients in both studies 
had symptoms well over a week and were hospital-
ized for 2 days and, hence, were likely over the peak 
of the viral load and displaying signs of dysregu-
lated host response (18). The median C-reactive pro-
tein levels on randomization were in the same range 
(130–150 mg/dL) in both studies, indicating ongoing 
inflammation and imbalance of the host response 
tilting toward persistent inflammation and immu-
nosuppression (17, 18). These are the patients where 
IL-6 receptor blockade may promote restoration of 
normal function, rather than further dampening the 
proinflammatory response.
We share several of the concerns raised by the authors 
in their well-written review on cytokine pathway 
blockade in bacterial and viral sepsis. It is likely that 
widespread and indiscriminate use of potent immu-
nomodulators could result in significant harm, as has 
been shown in previous sepsis trials that have enrolled 
patients with different stages of their disease. Based 
on our meta-analysis, it is clear that the two largest 
studies, which had similar inclusion criteria and were 
primarily performed in the same uniform healthcare 
setting, swing the pendulum toward benefit. Early use 
of IL-6 receptor blockade without concomitant steroid 
treatment has shown no benefit in several industry-
sponsored studies conducted at the beginning of the 
pandemic. It is also possible that genetic heterogeneity 
may play a role in the efficacy of the intervention, as 
evidenced by the negative studies conducted in Brazil 
and India. We agree with the authors that there is an 
even greater need to understand which patient popu-
lation may benefit most from these interventions. It is 
unclear whether, with the widespread usage of IL-6 re-
ceptor blockade (adopted in the U.K. National Health 
Service using the REMAP-CAP and RECOVERY study 
criteria), the feared increase in bacterial and fungal su-
perinfection will manifest with worsening outcomes 
or frequent reinfections and rehospitalization in sur-
vivors. There is an ongoing need for well-conducted 
observational trials to detect any harmful signal, and 
Figure 1. Twenty-eight-day mortality risk in patients admitted to hospital with coronavirus disease 2019 and treated with interleukin 
(IL)-6 receptor inhibitors or usual standard care. For statistical analysis, Mantel-Haenszel (M-H) statistics with fixed-effect model was 
used. df = degrees of freedom, REMAP-CAP = Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired 
Pneumonia. 
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furthermore, IL-6 receptor blockade should be evalu-
ated in more precisely described patient populations in 
different healthcare settings across the globe.
Beyond IL-6 receptor blockade, there are other po-
tential ways to manipulate the inflammatory response 
(19). Anakinra has been used to modulate the IL-1 
pathway, however, to date randomized controlled tri-
als failed to show any significant benefit in COVID-19 
(19). Notably, based on previous studies in sepsis, this 
intervention is likely to be successful if the patients 
have features of significant hyperinflammation (19). 
In this setting, population enrichment using multiple 
biomarkers is likely to lead to better results as preva-
lence of the hyperinflammatory phenotype of COVID-
19 ARDS is a lower than initially thought (15).
Another modality, which has promise with a pos-
itive signal from a randomized controlled trial, is 
blocking the intracellular pathway of the janus kinase 
1 (JAK1) and JAK2 signaling using baricitinib (19). 
The RECOVERY trial currently evaluates if adding 
this to the current U.K. standard of care would provide 
additional benefit. Combining cytokine modulation 
approaches could result in additional benefit; however, 
we agree with the authors that this could also lead to 
harm and should only be evaluated in clinical trials 
with robust safety reporting mechanisms.
Although the critical care literature is littered with 
negative studies in this arena, the COVID-19 pan-
demic is one of the first opportunities to investigate 
these potential therapies based on a single agent model, 
on the global scale. Some of the most recent results are 
encouraging, and we would like to highlight the need 
to keep an open mind, when evaluating cytokine mod-
ulation in COVID-19.
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